154 related articles for article (PubMed ID: 22634531)
21. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
Im SA; Lee KS; Ro J; Lee ES; Kwon Y; Ahn JH; Ahn JS; Kim JH; Kang HS; Shin KH; Noh DY; Park IA; Kim SB; Im YH; Ha SW
Breast Cancer Res Treat; 2012 Apr; 132(2):589-600. PubMed ID: 22094934
[TBL] [Abstract][Full Text] [Related]
24. Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
Firouzabadi D; Dehghanian A; Rezvani A; Mahmoudi L; Talei A
BMC Cancer; 2021 Jan; 21(1):47. PubMed ID: 33430808
[TBL] [Abstract][Full Text] [Related]
25. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Yin HF; Wang YH; Qin XQ; Zhang H; Li T; Ye JM; Liu YH
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):858-62. PubMed ID: 20137353
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
Gogas H; Pectasides D; Kostopoulos I; Lianos E; Skarlos D; Papaxoinis G; Bobos M; Kalofonos HP; Petraki K; Pavlakis K; Bafaloukos D; Fountzilas G
Clin Breast Cancer; 2010 Jun; 10(3):230-7. PubMed ID: 20497922
[TBL] [Abstract][Full Text] [Related]
27. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Semiglazov VF; Semiglazov VV; Dashyan GA; Ziltsova EK; Ivanov VG; Bozhok AA; Melnikova OA; Paltuev RM; Kletzel A; Berstein LM
Cancer; 2007 Jul; 110(2):244-54. PubMed ID: 17538978
[TBL] [Abstract][Full Text] [Related]
29. A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up.
Julka PK; Chacko RT; Nag S; Parshad R; Nair A; Koppiker CB; Xue FC; Barraclough H; Dhindsa N; Seth A; Majumdar A; Puri T
Breast Cancer; 2013 Oct; 20(4):357-62. PubMed ID: 22354450
[TBL] [Abstract][Full Text] [Related]
30. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study.
G Estevez L; Fortes JL; Adrover E; Peiró G; Margel M; Castellá E; Cuevas JM; Bernet L; Segui MA; Andreu X
Clin Transl Oncol; 2009 Jan; 11(1):54-9. PubMed ID: 19155205
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant gemcitabine therapy for breast cancer.
Sánchez-Rovira P; Jaén A; Dueñas R; Porras I; Martínez E; Medina B; Mohedano N; Fernández M; Lozano A
Clin Breast Cancer; 2002 May; 3 Suppl 1():39-44. PubMed ID: 12057045
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of the relationship between expression of survivin and effects of neoadjuvant chemotherapy in locally advanced breast cancer].
Fuzhong T; Nan L; Jiajia G; Miao L; Deqi Y
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1319-23. PubMed ID: 18701842
[TBL] [Abstract][Full Text] [Related]
34. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
35. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Gluz O; Nitz U; Liedtke C; Christgen M; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Bangemann N; Lindner C; Kuemmel S; Clemens M; Potenberg J; Staib P; Kohls A; von Schumann R; Kates R; Kates R; Schumacher J; Wuerstlein R; Kreipe HH; Harbeck N
J Natl Cancer Inst; 2018 Jun; 110(6):628-637. PubMed ID: 29228315
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.
Yardley DA; Zubkus J; Daniel B; Inhorn R; Lane CM; Vazquez ER; Naot Y; Burris HA; Hainsworth JD
Clin Breast Cancer; 2010 Oct; 10(5):367-72. PubMed ID: 20670921
[TBL] [Abstract][Full Text] [Related]
38. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Halim A; Wahba H
Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial.
Iwase S; Yamamoto D; Kuroda Y; Kawaguchi T; Kitamura K; Odagiri H; Teramoto S; Akazawa K; Nagumo Y
Anticancer Res; 2011 Apr; 31(4):1483-7. PubMed ID: 21508407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]